



# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

NASDAQ: **IDYA**  
January 2023

## IDEAYA Highlights

**Breakthrough Science** on transformative programs in Synthetic Lethality – an emerging area of precision medicine

**Broad Pipeline** of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

**Proven Management Team** with deep business and scientific experience has built leading oncology companies

**Pharma Strategic Partnerships** with GlaxoSmithKline<sup>1</sup>, including ~\$2 billion in potential cash milestones, Pfizer<sup>2</sup> and Amgen<sup>3</sup>

**Strong Balance Sheet** of ~\$394 million<sup>4</sup> with capital efficient model, anticipated to fund operations into 2026

**Analyst Coverage** by Capital One, Citi, Guggenheim, Jefferies, JP Morgan, Oppenheimer, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement;
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements;
- (3) Amgen Clinical Trial Collaboration and Supply Agreement;
- (4) Includes cash, equivalents and marketable securities as of September 30, 2022, pursuant to Form 10-Q filed November 8, 2022